501 related articles for article (PubMed ID: 25523125)
21. [Immune reconstitution inflammatory syndrome and rebound syndrome in multiple sclerosis patients who stopped disease modification therapy: current understanding and a case report].
Belova AN; Rasteryaeva MV; Zhulina NI; Belova EM; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2. Vyp. 2):74-84. PubMed ID: 28617365
[TBL] [Abstract][Full Text] [Related]
22. [Progressive multifocal leukoencephalopathy associated to natalizumab: the importance of magnetic resonance imaging in its early diagnosis].
Martí G; Río J; Rovira À; Auger C; Tintoré M; Sastre-Garriga J; Vidal A; Castilló J; Montalban X
Rev Neurol; 2015 Feb; 60(4):164-8. PubMed ID: 25670046
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children.
Vitaliti G; Matin N; Tabatabaie O; Di Traglia M; Pavone P; Lubrano R; Falsaperla R
Expert Rev Neurother; 2015; 15(11):1321-41. PubMed ID: 26513633
[TBL] [Abstract][Full Text] [Related]
24. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
25. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].
Gibelin N; Daelman L; Goulipian S; Wynckel A; Chaunu MP; Tourbah A
Rev Neurol (Paris); 2014 Jan; 170(1):48-50. PubMed ID: 24139244
[No Abstract] [Full Text] [Related]
26. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
[TBL] [Abstract][Full Text] [Related]
27. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Metz I; Radue EW; Oterino A; Kümpfel T; Wiendl H; Schippling S; Kuhle J; Sahraian MA; Gray F; Jakl V; Häusler D; Brück W
Acta Neuropathol; 2012 Feb; 123(2):235-45. PubMed ID: 22057786
[TBL] [Abstract][Full Text] [Related]
28. Progressive multifocal leukoencephalopathy after natalizumab discontinuation.
Fine AJ; Sorbello A; Kortepeter C; Scarazzini L
Ann Neurol; 2014 Jan; 75(1):108-15. PubMed ID: 24242357
[TBL] [Abstract][Full Text] [Related]
29. Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.
Bacchetta F; Mathias A; Schluep M; Du Pasquier R
Mult Scler; 2017 Feb; 23(2):300-303. PubMed ID: 28165319
[TBL] [Abstract][Full Text] [Related]
30. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.
Clifford DB; De Luca A; Simpson DM; Arendt G; Giovannoni G; Nath A
Lancet Neurol; 2010 Apr; 9(4):438-46. PubMed ID: 20298967
[TBL] [Abstract][Full Text] [Related]
32. Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS.
Lauda F; Fangerau T; Javaheripour-Otto K; Pinkhardt E; Kassubek J; Tumani H
J Neurol; 2015; 262(4):1055-7. PubMed ID: 25663412
[No Abstract] [Full Text] [Related]
33. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.
Igra MS; Paling D; Wattjes MP; Connolly DJA; Hoggard N
Br J Radiol; 2017 Jun; 90(1074):20160721. PubMed ID: 28362522
[TBL] [Abstract][Full Text] [Related]
34. Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Inflammatory Syndrome after Discontinuation of Fingolimod.
Piñar Morales R; Carrasco Garcia M; Gutierrez-Rojas L; Barrero Hernández FJ
Case Rep Neurol; 2022; 14(1):38-43. PubMed ID: 35350291
[TBL] [Abstract][Full Text] [Related]
35. Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod.
Evangelopoulos ME; Koutoulidis V; Andreadou E; Evangelopoulos DS; Kilidireas C
Int J Neurosci; 2016 Dec; 126(12):1097-102. PubMed ID: 26727713
[TBL] [Abstract][Full Text] [Related]
36. High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc.
Stork L; Brück W; Bar-Or A; Metz I
Acta Neuropathol; 2015 Mar; 129(3):467-8. PubMed ID: 25604548
[No Abstract] [Full Text] [Related]
37. MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS.
Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; de Vos M; Richert ND; Uitdehaag BM; Barkhof F; Killestein J;
J Neurol Neurosurg Psychiatry; 2016 Aug; 87(8):879-84. PubMed ID: 26369555
[TBL] [Abstract][Full Text] [Related]
38. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
[TBL] [Abstract][Full Text] [Related]
39. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
40. No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
Landi D; De Rossi N; Zagaglia S; Scarpazza C; Prosperini L; Albanese M; Buttari F; Mori F; Marfia GA; Sormani MP; Capra R; Centonze D;
Neurology; 2017 Mar; 88(12):1144-1152. PubMed ID: 28228569
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
